News & Articles

Key topics to include COVID-19 and infectious diseases, diabetes, sepsis, cardiovascular disease and personalized medicine as the global clinical community comes together to make the future healthier

Investment in state-of-the-art automation cements Abingdon Health’s position as a leading global rapid test manufacturer

Roche will access SpeeDx existing tests and technology to expand diagnostic products for the management of antibiotic resistance in STIs

Additional real-world data demonstrate meaningful outcomes for people living with diabetes who use Abbott's glucose sensing technology

The RECOVERY trial has shown that the cheap and widely available steroid cut deaths by one-third among patients critically ill with COVID-19

It's comprehensive SARS-COV-2 offerings span RT-PCR, high throughput RNA extraction, automation, ELISA and lateral flow based serology testing.

New kit is designed to enable short term prediction of pre-eclampsia and aid in diagnosis in the second and third trimesters of pregnancy

Discover how you can boost your research with screen-printed and interdigitated electrodes

To be in with a chance of winning a $500 Amazon Gift Card, simply cast your vote for the product that has made the most difference to your work

Our expert webinar series aims to help you get the most from your drug discovery research

The trial will study the use of ruxolitinib, a JAK inhibitor, to investigate its effect on reducing complications in deteriorating COVID-19 patients

A rare lung disease drug is being trialed to help fight COVID-19

The study is expected to begin enrolling in June with a target of approximately 450 patients globally

People who recovered from COVID-19 shows that most individuals had generated antibodies that were intrinsically capable of neutralizing the SARS-CoV-2 virus

Microsemi CRP hematology analyzers have been installed during COVID-19 ‘lockdown’ in POC locations to help reduce hospital admissions

The cPass™ – SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) Kit aims to detect the presence of neutralizing antibodies in an hour

Interim clinical study data shows ID NOW test performance of 94.7% sensitivity and 98.6% specificity

Driven by the gap in COVID-19 testing, the collaboration aims to create a fully disposable, rapid and handheld test for consumers